Nightingale Health Plc, stock exchange release, 21 March 2025 at 1:00 p.m. (EET)

 

Nightingale Health Plc (“Nightingale Health” or the “Company”) announced on 17 March 2025 that the Company had submitted a request to OTC Markets Group Inc. (“OTC Markets”) for the admission of the Series B shares (the “Shares”) to trading on the OTCQX International market so that the first trading day would be on 19 March 2025, at the earliest, and 24 March 2025, at the latest. The Company confirms that trading in the B Shares and ADRs commences today, 21 March 2025, on the OTCQX International market. The OTCQX is the highest quality tier of OTC Markets, and OTCQX International is reserved for companies whose share is already admitted to trading on a market outside the U.S. 

 

The trading code of the ADRs on the OTCQX International market is NHLTY and trading code of the B Shares on the OTCQX International market is NGHLF.

 

The Company announced on 17 March 2025 that the Company had established a sponsored Level 1 American Depositary Receipt (“ADR”) program in the United States, in order to enable efficient trading on the OTCQX International market. ADR is a convertible depositary receipt denominated in U.S. dollars and representing ownership of foreign shares in a non-U.S. company. Each ADR is issued by an American depositary bank and can represent one or more foreign shares or fractions of a share. ADRs are specially designed to make it easier for American investors to purchase, hold and sell non-U.S. securities. Citibank, N.A. acts as the depositary bank for Nightingale Health's ADR program and one ADR represents one share.

About OTC Markets Group Inc.

 

OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. OTC Markets Group Inc. operates three public markets: OTCQX® Best Market, OTCQB® Venture Market and Pink® Open Market.

 

For further information, please contact:

 

Teemu Suna, CEO

ir@nightingalehealth.com

 

About Nightingale Health

 

Nightingale Health has developed the world’s most advanced health check. Our solution provides risk detection for multiple chronic diseases from a single blood sample. Nightingale Health Check can be scaled to entire populations and it can replace many of the current routine disease risk assessments and health screening programs for chronic diseases. Detecting disease risks comprehensively and efficiently allows effective targeting and tracking of health interventions, and better prevention of chronic diseases. Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. With every sample we help to create a healthier world.

 

Nightingale Health operates globally with a parent company in Finland and eight subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The Company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. Read more: https://nightingalehealth.com/